Phase II study of capecitabine, irinotecan, and celecoxib in advanced colorectal cancer.

被引：0
|
作者：
El-Rayes, BF
Shields, AF
Vaishampayan, U
Heilbrun, L
Bekaii-Saab, T
Zalupski, MM
Philip, PA
机构：
[1] Karmanos Canc Inst, Detroit, MI USA
[2] Ohio State Univ, Columbus, OH 43210 USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3766
引用
收藏
页码：310S / 310S
页数：1
相关论文
共 50 条
  • [41] First-line Treatment With Capecitabine Combined With Irinotecan in Patients With Advanced Colorectal Carcinoma A Phase II Study
    Assy, Nimer
    Basher, Walid
    Chetver, Lika
    Shnaider, Julia
    Zidan, Jamal
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2012, 46 (04) : E27 - E30
  • [42] Phase II multicenter sequential study of oxaliplatin (O) and capecitabine (C) followed by irinotecan (I) and capecitabine (C) in first line advanced colorectal cancer (CRC).
    Cassinello, J
    Alvarez, JV
    García-López, MJ
    Pujol, E
    Colmenarejo, A
    de Segovia, F
    Marcos, F
    Filipovich, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 257S - 257S
  • [43] A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer
    Kato, Takeshi
    Mishima, Hideyuki
    Ikenaga, Masakazu
    Murata, Kouhei
    Ishida, Hideyuki
    Fukunaga, Mutsumi
    Ota, Hirofumi
    Tominaga, Shusei
    Ohnishi, Tadashi
    Amano, Masahiro
    Ikeda, Kimimasa
    Ikeda, Masataka
    Sekimoto, Mitsugu
    Sakamoto, Junichi
    Monden, Morito
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (02) : 275 - 281
  • [44] Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
    Pilar Garcia-Alfonso
    Manuel Chaves
    Andrés Muñoz
    Antonieta Salud
    Maria García-Gonzalez
    Cristina Grávalos
    Bartomeu Massuti
    Encarna González-Flores
    Bernardo Queralt
    Amelia López-Ladrón
    Ferran Losa
    Maria Jose Gómez
    Amparo Oltra
    Enrique Aranda
    BMC Cancer, 15
  • [45] A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer
    Takeshi Kato
    Hideyuki Mishima
    Masakazu Ikenaga
    Kouhei Murata
    Hideyuki Ishida
    Mutsumi Fukunaga
    Hirofumi Ota
    Shusei Tominaga
    Tadashi Ohnishi
    Masahiro Amano
    Kimimasa Ikeda
    Masataka Ikeda
    Mitsugu Sekimoto
    Junichi Sakamoto
    Morito Monden
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 275 - 281
  • [46] Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
    Garcia-Alfonso, Pilar
    Chaves, Manuel
    Munoz, Andres
    Salud, Antonieta
    Garcia-Gonzalez, Maria
    Gravalos, Cristina
    Massuti, Bartomeu
    Gonzalez-Flores, Encarna
    Queralt, Bernardo
    Lopez-Ladron, Amelia
    Losa, Ferran
    Jose Gomez, Maria
    Oltra, Amparo
    Aranda, Enrique
    BMC CANCER, 2015, 15
  • [47] Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer
    Yip, Pui Lam
    Fung, Wai Him Brian
    Lee, Francis Ann Shing
    Lee, Chak Fei
    Wong, Natalie Sean Man
    Lee, Shing Fung
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [48] Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients
    Moehler, Markus
    Sprinzl, Martin F.
    Abdelfattah, Murad
    Schimanski, Carl C.
    Adami, Bernd
    Godderz, Werner
    Majer, Klaus
    Flieger, Dimitri
    Teufel, Andreas
    Siebler, Juergen
    Hoehler, Thomas
    Galle, Peter R.
    Kanzler, Stephan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (04) : 449 - 456
  • [49] Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients
    Markus Moehler
    Martin F Sprinzl
    Murad Abdelfattah
    Carl C Schimanski
    Bernd Adami
    Werner Godderz
    Klaus Majer
    Dimitri Flieger
    Andreas Teufel
    Juergen Siebler
    Thomas Hoehler
    Peter R Galle
    Stephan Kanzler
    World Journal of Gastroenterology, 2009, 15 (04) : 449 - 456
  • [50] Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer
    Ardavanis, A.
    Kountourakis, P.
    Mantzaris, I.
    Malliou, S.
    Doufexis, D.
    Sykoutri, D.
    Thomopoulos, M.
    Fragos, I.
    Rigatos, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345